cancer%20pain
CANCER PAIN
Cancer pain is an unpleasant sensory & emotional experience due to actual or potential tissue damage in patients with cancer.
Effective pain management in cancer patients with pain is an essential part of oncologic management due to increasing evidence of survival.
Pancreatic, head & neck cancer has a high prevalence of cancer pain.
During initial evaluation, follow-ups and new therapy initiation of patients with cancer, it is essential that they will be screened & evaluated for pain.

Cancer Pain Drug Information

Drug Information

Indication: Neuropathic pain in adults. Adjunctive therapy in adults w/ partial seizures w/ or w/o secondary generalisatio...

Indication: Symptomatic relief of moderate to severe pain, especially associated w/ neoplastic disease, MI & surgery. ...

Indication: Peripheral & central neuropathic pain, generalised anxiety disorder (GAD) in adults. Adjunctive therapy in...

Indication: Management of chronic pain & intractable pain in patients requiring continuous opioid administration for a...

Indication: Depression including depression w/ associated anxiety. Generalized anxiety disorder (GAD) including long-term ...

Indication: Adjunctive therapy in treatment of partial seizures w/ & w/o secondary generalization in adults & chil...

Indication: Moderate to severe pain.

Indication: Moderate to severe pain.

Indication: Management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain.

Indication: Severe acute & chronic pain. Painful diagnostic or therapeutic measures.

1  /  6
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 03 Sep 2020
Real-world systemic sequential therapy with regorafenib confers survival benefits in patients with advanced hepatocellular carcinoma (HCC) who failed first-line sorafenib, consistent with previous clinical trial, according to a study in Korea.
5 days ago
A recent study has found no significant impact of 5α-reductase inhibitors on Gleason grading, with no difference in mortality seen among users and nonusers in each Gleason group.